Generian Pharmaceuticals utilizes a proprietary drug discovery platform to identify orally bioavailable small molecules that modulate protein stability through activation, stabilization, or degradation. This approach targets diseases with high unmet needs, particularly those currently treated with biologics, enhancing patient access and reducing treatment costs.
Funding
$13M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, particularly those currently treated with biologics, have high unmet needs due to limitations in patient access, high treatment costs, and challenges in achieving optimal drug titration. Biologic drugs often require intravenous administration, limiting convenience and accessibility for patients.
Solution
Generian Pharmaceuticals is developing orally bioavailable small molecule therapeutics that modulate protein stability to address diseases currently dominated by biologics. Their proprietary drug discovery platform identifies small molecules that can activate, stabilize, or degrade target proteins, offering a more convenient and cost-effective alternative to biologics. By focusing on small molecules, Generian aims to improve patient access, reduce treatment costs, and enable more precise drug titration compared to traditional antibody-based therapies. The company's approach allows for screening proteins in their native cellular environment, potentially unlocking previously undruggable targets.
Target Audience
The primary target audience includes patients with diseases currently treated with biologics, as well as pharmaceutical companies seeking novel small molecule therapeutics for difficult-to-drug targets.
Features
- Proprietary drug discovery platform for identifying small molecules that modulate protein stability
- Focus on orally bioavailable small molecules for improved patient convenience
- Capability to screen proteins of interest in their native cellular environment
- Identification of target binders through highly translational phenotypic screening
- Pipeline of first-in-class drug candidates that therapeutically modulate target protein structure and/or dynamics
- Programs targeting both clinically validated targets and novel targets through a research collaboration agreement